Depression, Postpartum
Sage Therapeutics Rejects Biogen’s Acquisition Bid, Initiates Strategic Review
Sage Therapeutics, Biogen, acquisition rejection, strategic alternatives, ZURZUVAE, postpartum depression, pharmaceutical industry, M&A
Sage Therapeutics Rejects Biogen’s Acquisition Proposal, Remains Open to Future Deals
Sage Therapeutics, Biogen, Acquisition Proposal, Postpartum Depression, ZURZUVAE, Neurodevelopmental Disorders, Neuropsychiatry
Biogen Proposes Acquisition of Sage Therapeutics in $442 Million Deal
Biogen, Sage Therapeutics, acquisition, neuro biotech, zuranolone, postpartum depression, major depressive disorder
Biogen and Sage Discontinue Plans for Major Depressive Disorder Approval for Zurzuvae
Biogen, Sage Therapeutics, Zurzuvae, postpartum depression, major depressive disorder, FDA approval